Timothy Rothwell


Timothy G. Rothwell is currently the Chairman of Emisphere Technologies Inc. (OTC: EMIS), a commercial stage, specialty pharmaceutical company since early 2012 and prior to that a Director of the Company from late 2009. Mr. Rothwell is also the Chairman of Speracura LLC, a healthcare consulting company from 2009 and the President of the SDHB PHEOPARA Coalition from 2016.

Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S.  He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S.  From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.

Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.

He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.

He also served as the Chairman of the Pheo Para Alliance from 2009 to 2014 which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.


Nicholas Rothwell

Vice President & Treasurer

Mr. Rothwell is currently the President of Buckingham Supply Chain Services, LLC and is providing consulting services to the Biopharmaceutical industry.

Nick has been working in the life sciences industry for over 30 years and has acquired extensive experience, knowledge and expertise in Supply Chain, Logistics, Manufacturing and Operations Management during that time. 

Prior to assuming his current role, Rothwell was the EVP of Technical Operations at Archimedes Pharma, a privately held specialty pharmaceutical company with a diverse portfolio of products.  Nick was a member of the Global Leadership Team and an officer of the company.

Spanning a long career, Rothwell held senior level positions of increasing responsibility with Novartis, Pharmacia and Wyeth Pharmaceuticals where he contributed to the launch of the largest vaccine in the world.

Mr. Rothwell is a recognized leader in developing, implementing, and effectively managing end–to–end fully integrated supply chains and specializes in improving the overall performance across the supply network.  His primary focus is to manufacture a quality product, achieve competitive levels of service and ensure continuity of supply for a portfolio of products while effectively managing the costs associated with same.

Nick earned a technical degree in Materials Management while serving in the Royal Air Force and is certified in Production & Inventory Management by APICS, The Association for Operations Management.

As a relative of a patient, he is motivated and passionate about ensuring early detection through education and sponsoring research that achieves our objective of finding better treatment options and/or a cure.  Mr. Rothwell has dedicated his professional life to making a difference in and improving the quality of people’s lives.


Rick Keefer


Rick is currently the Global Chief Business Development Officer at Publicis Health.  

Rick is a 30-year industry veteran with broad-based experience in leading commercial operations.

Prior to joining Publicis Health, he was Senior Vice President, Commercial Operations with Biovail Corporation. Rick also served as Vice President, Sales for Pharmacia Corporation. Prior to Pharmacia, Rick spent 11 years at Wyeth-Ayerst Laboratories where he held a number of senior positions in both of the company’s institutional and primary care divisions.

Rick is passionate about the vital contribution the biopharma industry makes in helping people live longer and healthier lives. He holds a deep-seated belief that our calling is upright, benevolent, and admirable. According to Rick, every member of the Publicis team can sleep well at night knowing that the work they do each day has a positive effect on the lives of people in their nation, community, and family. It’s an honor and privilege we take seriously.


Sheila Buchbinder

Board Member

Dr. Buchbinder joined the board of directors with extensive experience as a board-certified obstetrician gynecologist.  

In addition, her private practice specialized in laparoscopic surgery.  

She has acted as a consultant both at the state and federal level in relation to women’s healthcare issues.  

She has taught and published on laparoscopic surgery and participated in the design and development of innovative medical technologies.

Dr. Buchbinder has received the American Woman’s Medical Association and Lang Publication awards.  

Dr. Buchbinder is a graduate of Brown University’s Program in Medicine and completed her training at Columbia Presbyterian Medical Center, Sloane Hospital for Women.


Curtis Quigley

Board Member

Curtis Quigley is a senior biopharmaceutical executive with twenty three years of success within the commercial operations and global health access areas.

He currently is the Senior Vice President of Commercial Operations for Celularity, Inc. Celularity is focused on harnessing the power of the living cell with leading edge technologies to amplify the body’s ability to fight disease, heal and regenerate itself. Celularity combines innovative assets and research in cell therapy, functional regeneration and biosourcing to develop leading therapeutic products and services that treat serious, life-threatening diseases.

Prior to joining Celularity Inc., Mr. Quigley was Vice President and General Manager , Global Health Access for Celgene Corporation and Vice President of Sales Operations and Integrated Health for the US business. Previous to Celgene Corporation, Curtis held leadership positions at Pharmacia, Rhone-Poulenc Rohr and Novartis Pharmaceuticals Corporation.

Mr. Quigley is focused on supporting the commercial efforts of companies and organizations working on improving treatment options for patients.

Alan Rubino

Board Member

Alan L. Rubino joined Emisphere in 2012 as President and Chief Executive Officer. Upon joining, he was also appointed as Class II Director of the Company. Mr. Rubino’s career spans over 30 years at every level of the biopharmaceutical industry.

Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and then sold the asset to Renaissance Pharmaceuticals, for a multiple of three times sales. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products.  Rounding out his background, he had also been President and COO of another publicly-held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the healthcare sector with two other public companies, Cardinal Health and PDI Inc.

A major portion of Mr. Rubino’s highly successful career includes his twenty-four years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies.  At Roche, he was the youngest corporate officer ever designated and an 11 year member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning. Among his many accomplishment was launching the world’s first biologic product, Roferon-A (interferon-alfa 2a) in 1986.

Mr. Rubino currently serves on the Corporate Boards of Vericel Inc., Genisphere, Inc. and Sanuwave Health, Inc. For the past 17 years, he has served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.